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Abstract  
 
There is increasing epidemiologic and molecular evidence that cutaneous 
melanomas arise through multiple causal pathways. The purpose of this study was to 
explore the relationship between germline and somatic mutations in a population-based 
series of melanoma patients to reshape and refine the divergent pathway model for 
melanoma. Melanomas collected from 123 Australian patients were analyzed for MC1R 
variants and mutations in the BRAF and NRAS genes. Detailed phenotypic and sun 
exposure data were systematically collected from all patients. We found that BRAF-
mutant melanomas were significantly more likely from younger patients and those with 
high nevus counts, and were more likely in melanomas with adjacent neval remnants. 
Conversely, BRAF-mutant melanomas were significantly less likely in people with high 
levels of life-time sun exposure. We observed no association between germline MC1R 
status and somatic BRAF mutations in melanomas from this population. BRAF-mutant 
melanomas have different origins from other cutaneous melanomas. These data support 
the divergent pathways hypothesis for melanoma, which may require a reappraisal of 
targeted cancer prevention activities.   
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Introduction 
 
Cutaneous melanoma is a common form of cancer arising from the pigment cells of 
the skin. Risk factors for melanoma include large numbers of melanocytic nevi, fair skin 
and sunlight exposure (Siskind et al., 2005).  While solar ultraviolet radiation (UVR) is the 
principal environmental risk factor for these cancers, there is increasing evidence that the 
effect of sunlight on pigment cells is not the same for all people. Epidemiologic data 
support the concept that melanomas may develop through one of several pathways. 
Increasingly, it appears that the molecular profile (particularly for oncogenes BRAF and 
NRAS) of cutaneous melanomas reflects these causal pathways, typified by different 
patterns of associations with host and environmental risk factors (Curtin et al., 2005; 
Thomas et al., 2007; Whiteman et al., 2006; 2003). For example, a recent study 
suggested that melanomas occurring in younger people with high early-life ambient UVR 
exposure have a high frequency of BRAF mutation, whereas melanomas arising in 
people with high levels of lifetime UVR exposure are associated with NRAS mutations 
(Thomas et al., 2007).  
The melanocortin-1 receptor (MC1R) gene is a key determinant of human 
pigmentation and is highly polymorphic with specific variants linked to red hair and 
melanoma risk (Palmer et al., 2000; Sturm et al., 2003). Recently, a synergistic 
relationship between germline MC1R variants and somatic BRAF mutations was 
suggested (2006), whereby MC1R variant genotypes conferred a significantly increased 
risk of developing BRAF-mutant melanoma in skin not damaged by sunlight. Recent work 
by Fargnoli et al (2008) further examined the role of MC1R in the Italian population and 
found patients with MC1R variants had a higher risk of carrying BRAF mutations in 
tumors from chronically sun-exposed sites (OR 13.9, 95% CI = 1.5-133.3)  than 
intermittently sun exposed sites (OR 3.4, 95% CI = 0.8-14.0) although this was not 
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significantly different. They reported increased risks for BRAF–mutant melanoma 
associated with variants of MC1R, not only for R variants, but also for r.  
Here, we present the findings of the first study to explore the relationship between 
germline MC1R status and somatic BRAF mutations in melanomas from a susceptible 
population exposed to very high levels of ambient UVR. 
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Results 
 
Subject Characteristics 
For this analysis (n=123 patients), mean age at diagnosis was 56.4 years and 48% 
of patients were females. The percentages of histological subtypes were 62% SSM, 1.6% 
NM, 28% LMM and 8.9% unclassified melanoma. No acral lentiginous melanoma, 
spitzoid or nevoid lesions were included in this study. Tumors were generally thin; 85% of 
the lesions were Clark level I or II, and 74% had Breslow thickness <0.75 mm.  
 
BRAF and NRAS Mutational Frequencies 
Mutually exclusive BRAF-mutant and NRAS-mutant tumors occurred at 
frequencies of 31.5% and 3% respectively.  Detection of mutations was based on cut-offs 
imposed using DNA from whole blood buffy coat as wild-type controls (Figure S1)  and 
previous studies which have demonstrated the sensitivity of the Sequenom MassArray 
platform to detect mutant alleles as low as 1.5–3% of the analyzed sample (Vivante et al, 
2007). Due to the low number of tumors with NRAS mutations no further statistical 
analysis was performed using these samples.  
 
Clinical and Pathologic Characteristics of BRAF-mutant Lesions 
Overall, the mean age at diagnosis for patients carrying a BRAF V600 mutation 
was 47.6 years compared with 60.8 years for wild-type cases (t-test p<0.001) (Table 1), 
and similar patterns were observed within the pre-specified age groups (stratum <50 
years: mean age BRAF V600 35.4 years vs wild-type 42.9 years; stratum 50+ years 
mean age BRAF V600 58.6 years vs wild-type 66.5 years). There was no association 
between gender and BRAF V600 mutation. The prevalence of BRAF V600 mutations 
differed by histological subtype, with only 12% of LMM carrying BRAF mutations 
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compared with 45% of SSM and 50% of NM (Fishers Exact p=0.001). While 20% of in 
situ melanomas carried BRAF V600 mutations compared with 50% of invasive lesions 
(Chi-Square p=0.02), we found no evidence that the prevalence of BRAF V600 mutation 
increased further with increasing depth of invasion.  
 
Phenotypic and environmental factors associated with BRAF Mutations 
Compared with patients who had 0-15 nevi, those with 16-60 nevi were 10-fold 
more likely to have BRAF V600 mutant melanoma and patients with >60 nevi had 
similarly increased risks of harboring a mutation (Table 2). Furthermore, melanomas with 
evidence of adjacent neval remnants were more likely to have a BRAF V600 mutation 
(OR 2.7, 95% CI = 1.2-6.2). The ability to develop a tan was also associated with tumors 
that carried BRAF V600 mutations (OR 4.3, 95% CI 1.8-10.4). Freckling, hair and eye 
color were not significantly associated with BRAF V600 mutational status. 
We found no association between anatomic site (head and neck vs trunk and 
limbs) and BRAF V600 mutation, however we found that BRAF V600 mutant melanomas 
were statistically significantly less likely to occur in people in the highest groups of 
cumulative sun exposure or actinic keratosis counts (Table 2). Similarly, BRAF V600 
mutant melanomas were less common among people who reported large numbers of 
sunburns as adults, although this was not statistically significant. 
 To assess which of these phenotypic and environmental factors was most 
predictive of BRAF V600 mutation status, we fitted multivariable logistic regression 
models using a variety of supervised algorithms. Regardless of the approach to model-
fitting (forwards, backwards, stepwise), the final model included terms only for total nevus 
count and the presence of contiguous neval remnants (in addition to the sampling 
variables, age group and sex) as the best predictors of BRAF V600 mutation status for 
melanoma (Table 3). 
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 We repeated all of the analyses restricted only to the patients with invasive 
melanomas, and found essentially similar patterns to those reported above, albeit with 
reduced precision (Table S1). 
 
Frequency of MC1R Variants  
74.5% of melanoma patients carried one of the eight common MC1R variants, 
consistent with previous reports in this population. The estimated allele frequency of 
measured variants in this population is presented in Table 4. There was no association of 
MC1R variants with gender, histological subtype and invasive classification. 
 
Phenotypic and environmental factors associated with MC1R variants 
Of a number of phenotypic characteristics for which we sought associations with 
MC1R (Table S2) the only characteristic statistically significantly associated with MC1R 
status was freckling density on both the face and arms (few facial freckles OR 2.1, 95%CI 
0.8-5.5; many facial freckles OR 9.8, 95%CI 2.4-39.4 p=0.03). While not statistically 
significant due to small numbers, red hair was only observed in patients carrying MC1R 
variants. There was no increase in the number of total body nevi or actinic keratosis in 
patients carrying MC1R variants, nor was there any association with sun exposure (Table 
S2). 
 
BRAF and MC1R  
There was no association between germline MC1R variants and somatic BRAF 
V600 mutations in tumor samples (Table 5). Lesions were categorized into intermittently 
and chronically sun-exposed body sites but no difference in the rates of BRAF V600 
mutations was observed. As we found a lower incidence of BRAF V600 mutations in 
LMM lesions we repeated the analysis excluding this sub-type, we still found no observed 
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difference in the prevalence of BRAF V600 mutations amongst patients carrying MC1R 
variants (Table S3).  Due to the age structure of our cases we further investigated the 
relationships between MC1R and somatic BRAF V600 mutations overall and within broad 
strata of actinic keratosis and sun exposure history (Table 5). However, there was no 
observed difference in the prevalence of BRAF V600 mutations amongst patients 
carrying MC1R variants compared to patients with wild-type MC1R. We also excluded the 
possibility of the LMM subtype confounding the data by excluding them (Table S3). We 
further analyzed the relationship between germline MC1R variants and somatic BRAF 
mutations restricted only to patients with invasive melanomas and found no association 
between the prevalence of BRAF V600 mutations amongst patients carrying MC1R 
variants compared to patients with wild-type MC1R (Table S3).  
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Discussion 
 
We have analyzed melanoma samples from an Australian population to further 
explore the ‘divergent pathway model’ for melanoma. This model proposes at least two 
different causal pathways to melanoma development, one arm pertaining to host 
susceptibility and nevus growth and another arm associated with chronic sun exposure. 
Our results accord with this model, since we found that melanomas with and without 
BRAF V600 mutations displayed significantly different associations with a range of 
phenotypic, histological and environmental factors. We found that melanomas harboring 
BRAF V600 mutations were more likely among younger patients and those with high 
nevus counts, and were more likely to occur in melanomas with adjacent neval remnants. 
Melanomas with BRAF V600 mutations were less likely to occur in people with evidence 
of high-levels of life-time sun exposure such as self-reported sun exposure history and 
nurse counts of actinic keratosis. In keeping with this observation, melanomas of the 
lentigo maligna subtype exhibited a lower frequency of BRAF V600 mutations. Patients 
with tumors carrying BRAF V600 mutations had the ability to develop a tan, suggesting 
intact pigmentation pathways. While BRAF V600 mutant melanomas were more likely to 
occur in younger people, it was notable that such lesions were more likely to be invasive 
compared to wild-type melanomas. It has been suggested that BRAF V600 mutations are 
induced in melanocytes as a result of childhood sun exposure (Thomas et al., 2007). 
Presumably a proportion of these transformed cells progress to melanoma, accounting 
for the younger mean age of diagnosis. 
Only a few studies to date have examined determinants for BRAF V600 mutations 
in melanoma (Fargnoli et al., 2008; Landi et al., 2006; Thomas et al., 2007). Our findings 
are in substantial agreement with those of a study performed in North Carolina by 
Thomas et al (2007), although we observed no association between anatomic site and 
 10
prevalence of BRAF V600 mutations. It is important to note that the lack of association 
here most likely reflects the sampling strategy used in the parent study from which these 
samples were derived (Whiteman et al., 2003). Patients in the parent study were 
frequency sampled within strata of age, sex and anatomic site to ensure similar numbers 
of younger and older patients for each body site. In our sample, the mean age of patients 
with melanoma of the head and neck was actually younger (55 years) than that of 
patients with melanoma of the trunk (58 years). This was entirely due to the sampling, as 
our previous studies in the same population have shown that on average, patients with 
head and neck melanomas are significantly older than those with melanomas of the trunk 
(Siskind et al., 2005). Our findings differ from Fargnoli et al (2008), for which the 
published data (their Table 2) suggest no association between nevus count and BRAF 
mutation when nevus count was dichotomized at the median.  
We sought to explore the biological differences between in situ and invasive 
melanomas by reanalyzing the dataset restricted only to invasive melanomas. The 
findings are essentially unchanged, although with the reduced sample size, the precision 
of risk estimates is less than the originally reported findings (Table S1).  We sought to 
explore the effects of age and anatomical site in melanoma causation by intentionally 
sampling patients from within pre-defined strata. One consequence of this is that in 
Queensland at least, younger patients with melanocytic lesions tend to present for 
medical care early, especially for facial melanomas. As a result, most melanomas among 
young people are thin lesions, particularly on the head and neck.  
 Importantly, our findings differ from the studies by Landi and colleagues (Fargnoli 
et al., 2008; Landi et al., 2006), which were based on sequenced MC1R and BRAF 
genes and were restricted only to invasive melanomas.  We observed no association 
between germline MC1R status and the prevalence of somatic BRAF V600 mutations in 
melanomas, even after classifying lesions into intermittent and chronic sun-exposed 
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sites. We further investigated the relationships between MC1R and BRAF V600 
mutations using the number of actinic keratosis and self-reported sun exposure history as 
proxies for total sun exposure, however we found no evidence of any difference in the 
prevalence of BRAF V600 mutation by MC1R status. It is possible that the discordant 
study findings reflect underlying differences in the populations, although the small sample 
sizes for each study means that chance cannot be excluded. Clearly, further studies of 
substantially larger size are warranted to clarify the possible biological relationship 
between germline MC1R status and somatic BRAF mutations.  
 Strengths of our study include the population-base sampling frame and the 
detailed epidemiologic data (including nurse counts of nevi and actinic keratosis blind to 
genotype status) accompanying the tumor specimens. In particular, we intentionally over-
sampled younger patients with melanoma to ensure that we could account for possible 
age-specific differences in associations between likely causal factors and site of 
melanoma. The prevalence of somatic BRAF V600 mutation-positive samples (31.5%) 
was consistent with previous reports (Thomas et al., 2007), and the distribution of MC1R 
variants was very similar to earlier reports from Queensland (Duffy et al., 2004).  
A limitation of this study was the restricted number of samples for analysis, due to 
the use of tissue samples for earlier immunohistochemical investigations (Lee et al., 
2006; Richmond-Sinclair et al., 2008). To assess possible selection bias, we compared 
the prevalence of phenotypic (including skin type, hair and eye color, freckling density 
and counts of nevi and actinic keratosis) and histological (contiguous neval remnants, 
thickness, anatomic site) characteristics as well as the age and sex among those 
participants with tumor blocks available for analysis and those without. The distributions 
were similar in each group of patients (data not shown).   
A further limitation is that we did not perform full sequencing of the entire MC1R gene. 
However, our distribution of variants (Table 4) is very similar to the largest sequencing 
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effort so far completed in Caucasian populations (Kanetsky et al, 2006). The MC1R 
variants genotyped in the present study comprise over 93% of the non-synonymous 
changes observed in the Kanetsky study, which analyzed a far more ethnically diverse 
sample than our study (USA, Italy and Australia). Therefore we do not believe the rare 
MC1R variants not covered in our investigation would markedly affect our risk estimates; 
assessment in a large population-based sample is necessary to conclusively address this 
issue.  
In light of these findings we have refined and extended the divergent molecular 
pathway model by explicitly incorporating mutational events as well as additional 
environmental and phenotypic data (Figure 1). The initiation event in this model is early-
life sun exposure, which has previously been shown using migrant studies to hold the 
greatest risk for developing melanoma later in life (Whiteman et al., 2001). Work by 
Bauer et al (2007) has shown that congenital nevi, which develop independently of sun 
exposure, lack BRAF V600 mutations, while acquired nevi are associated with sun 
exposure in early life (English et al., 2006) and commonly harbor BRAF V600 mutations 
(Pollock et al., 2003).  
Several studies have speculated that host factors may underlie susceptibility for 
melanocyte proliferation and nevus formation. Work by Bataille et al (2007) explored 
telomere length in white blood cells as a possible predictor of nevus counts. Subjects with 
high nevus counts exhibited longer telomeres, and it has been inferred that such 
individuals may have increased cellular replicative potential. It is presumed that this is not 
just limited to melanocytes. Genome-wide linkage studies for nevus counts have 
identified several regions of linkage on chromosomes 2, 5, 8, 9, and 17. Of particular 
interest was the association of the CDKN2A locus with nevus formation (Falchi et al., 
2006; Zhu et al., 2007). Mutations and loss of p16 (one product encoded by CDKN2A) 
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are well documented in melanoma, and it appears that p16 contributes to melanoma 
pathogenesis through pathways that escape routine senescence. 
In conclusion, our work provides further support for the divergent pathway 
hypothesis for melanoma by demonstrating that BRAF V600 mutant melanomas occur 
more commonly in younger individuals and those with high nevus counts, and occur in 
melanomas with contiguous neval remnants. These findings suggest that a sub-group 
exists within the general population at risk of BRAF V600 mutant melanoma, and that 
these people may be characterized by distinct phenotypic attributes. Understanding the 
interacting roles of sunlight, susceptibility and BRAF mutation on melanoma development 
is the aim of our continuing research.  
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Materials & Methods 
 
Subjects 
We compared the prevalence of BRAF and NRAS mutations in formalin-fixed 
paraffin-embedded melanoma specimens from 123 patients ascertained from the 
Queensland Cancer Registry. Detailed description of subject selection and data collection 
for this study have been described previously (Whiteman et al., 2003). Briefly, eligible 
patients were residents of greater Brisbane, Australia (latitude 27oS) who were diagnosed 
with a histologically confirmed primary cutaneous melanoma between January 1, 1998, 
and December 31, 1999. Patients were intentionally sampled within pre-defined strata of 
age (<50 years, >50 years) and sex to ensure similar distributions for these variables in 
the ensuing epidemiologic analyses. Those with metastatic melanoma or a previous 
diagnosis of melanoma were not eligible. Of 452 eligible patients for the initial 
epidemiologic study, 387 (86%) completed questionnaires and 328 (73%) provided 
written informed consent to obtain specimens of archived melanoma tissue. This analysis 
was restricted to 123 patients for whom sufficient material was remaining for mutation 
analysis. The age and sex distribution of the 123 patients that were genotyped for BRAF 
was the same as for the 264 patients who were not. 
Approval to perform the study was given by the Human Research Ethics 
Committee of the Queensland Institute of Medical Research and the Queensland Cancer 
Registry. The declarations of Helsinki protocols were followed and all participants gave 
their written consent to take part.   
 
DNA Isolation 
Hematoxylin and eosin stained sections of each patient’s melanoma were 
assessed for areas of normal and tumor tissue, and the percentage of tumor cells was 
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recorded. Formalin-fixed paraffin-embedded tissue sections were dissected to select 
areas where melanoma cells dominated over stromal cells. Sections (20 μm) were cut 
from each tumor block and deparaffinized in xylene and washed twice in absolute 
ethanol. DNA was isolated using Qiagen DNeasy Tissue Kit (Qiagen, Germany), with 
additional proteinase K digestion at 55oC for 48 hours. DNA was extracted from whole 
blood buffy coat and melanoma cell lines using Qiagen DNeasy kits (Qiagen). DNA 
quantification was determined by spectrophotometry (Nanodrop, Wilmington, DE) and 
DNA quality was checked using 2% agarose gels (Amresco, Solon, OH). 
 
MC1R, BRAF and NRAS Genotyping 
Genotyping was performed using the MassArray platform (Sequenom Inc, San 
Diego, CA). An optimized multiplex assay of all common and a subset of rare known 
variants of MC1R were used as previously described (Duffy et al., 2004). Only non-
synonymous variants or insertions/deletions in MC1R were considered in this analysis. 
BRAF V600 and NRAS Q61 mutations were detected with single base extension 
or allele-specific assays, using the iPLEX genotyping format (Sequenom) (see Table S4 
for primer details). Samples were analyzed in duplicate with genotyping repeated three 
times to confirm mutation status.  Melanoma cell lines previously characterized in (Stark 
and Hayward, 2007) were used in this study as positive controls for the MC1R, BRAF 
and NRAS genotyping assays.  DNA from whole blood buffy coat was used as wild-type 
controls in the BRAF and NRAS genotyping assays (Figure S1). We have only examined 
the BRAF V600 mutations, other rare changes such as D594, L597, and L584 were not 
examined in this study. 
 
Phenotypic characteristics and sun exposure history 
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Relevant exposure data (including sun exposure history and skin sensitivity) were 
collected from study participants through a self-completed, structured questionnaire as 
described previously (Whiteman et al., 2003). In addition to background information, we 
asked participants to report their occupational history (including periods of study and 
unemployment) since leaving school. We asked participants to report how much time 
they spent outdoors in the sun in summer on work and non-work days for each period of 
employment. Participants were asked to report their nevus burden as a teenager and the 
number of previous treatments for keratinocyte cancers (basal cell carcinomas and 
squamous cell carcinomas).  Finally, a single trained research nurse who was unaware of 
the study hypotheses examined each participant. The nurse recorded hair and eye color 
and counted melanocytic nevi and solar keratoses. Nevi were defined as pigmented 
macules or papules of any size and distinguished from freckles and seborrheic keratoses. 
Numbers of nevi were counted on the head and neck, the upper limbs, and the trunk and 
were classified according to size as less than 5 mm or greater than or equal to 5 mm in 
diameter by use of a transparent plastic stencil. Freckles were defined as irregular but 
sharply demarcated macules, usually small (<4 mm), uniformly pigmented (tan/light 
brown), and usually occurring in clusters on exposed body sites. The density of freckling 
on the face was categorized on a four-point scale. Solar keratoses, defined as superficial, 
rough scaly areas with erythematous background and ill-defined margins were counted 
separately on the dorsal surfaces of the hands, forearms, and face. 
  
Statistical analysis 
We calculated the amount of sun exposure received on working days (hereafter 
“occupational exposure”) by multiplying the duration of each employment period (in 
weeks) by the number of days per week worked, and the number of hours per day spent 
outdoors in the sun on workdays.  Ambient recreational exposure was calculated in a 
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similar manner using self-reported estimates of sun exposure on non-work days in each 
employment period.  We summed occupational and recreational sun exposures across all 
employment periods after age 20 years up until age of diagnosis to derive cumulative 
totals for each pattern of exposure. Total ambient sun exposure for each participant was 
the sum of cumulative occupational and recreational sun exposure.  
We performed simple cross-tabulations and calculated Pearson’s chi-square 
and/or Fischer’s exact test (for cells with expected count of less than 5) as a measure of 
statistical association.  We used multivariable logistic regression to calculate odds ratios 
(ORs) and 95% confidence intervals (CIs) as measure of association between 
patient/tumor characteristics and BRAF mutation status (V600 mutant vs V600 wild-type). 
We included terms for age stratum (<50 years, >50 years) and sex to control for possible 
confounding introduced by the study design.  We conducted supervised model-fitting to 
identify the best model to predict BRAF V600 mutation status using forward, backward 
and stepwise elimination procedures. P-values less than or equal to 0.05 were 
considered as statistically significant and all such tests were 2-sided.  All analyses were 
performed using the SAS 9.1 statistical software package (SAS institute, Cary, NC). 
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Table S1. Association between phenotypic factors and BRAF V600 mutations in invasive 
melanoma only 
 
Table S2. Phenotypic and environmental factors interacting with MC1R variants 
 
Table S3. Association between MC1R and BRAF stratified by sun exposure and 
excluding LMM lesions 
 
Table S4. Primer sequences used for BRAF and NRAS genotyping  
 
Figure S1. Detection of BRAF V600 mutations used DNA from whole blood buffy coat as 
wild-type controls. Mutations were detected if the percent of primer extension was above 
control samples (above dotted line). 
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Table 1. Clinical and pathologic characteristics of patients and lesions  
 
Characteristic 
 
BRAF 
V600 
 mutation 
n= 40 
BRAF 
V600 
wild-type 
n= 83 
MC1R  
(any 
variant) 
n= 90 
MC1R 
wild-type# 
n=33 
MC1R (r/wt 
or r/r) 
n=33 
MC1R (any 
R allele) 
n=57 
Age at 
diagnosis (y) 
Mean + SD, y 
 
47.5  
+ 14.1 
 
60.7  
+ 13.4 
 
56.1 
 + 14.7 
 
57.3  
+ 15.8 
 
56.3 
 + 15.8 
 
56  
+ 14.2 
Gender, n (%) 
Male 
Female 
 
17 (27) 
23 (39) 
 
47 (73) 
36 (61) 
 
49 (76) 
41 (69) 
 
15 (23) 
18 (31) 
 
18 (37) 
15 (37) 
 
31 (63) 
26 (63) 
Histological 
subtype,  
SSM 
NM 
LMM 
Not stated 
 
 
34 (45) 
1 (50) 
4 (12) 
1 (9) 
 
 
42 (55) 
1 (50) 
30 (88) 
10 (91) 
 
 
56 (74) 
1 (50) 
24 (71) 
9 (82) 
 
 
20 (26) 
1 (50) 
10 (29) 
2 (18) 
 
 
22 (39) 
0 (0) 
8 (33) 
3 (33) 
 
 
34 (61) 
1 (100) 
16 (67) 
6 (67) 
Pathological 
Classification,  
In situ 
Invasive 
 
 
12 (21) 
28 (42) 
 
 
45 (79) 
38 (58) 
 
 
39 (68) 
51 (77) 
 
 
18 (32) 
15 (23) 
 
 
14 (36) 
19 (37) 
 
 
25 (64) 
32 (63) 
Clark level 
1 
2 
>=3 
not stated 
 
13 (20) 
18 (46) 
8 (50) 
1 (33) 
 
52 (80) 
21 (54) 
8 (50) 
2 (67) 
 
46 (71) 
29 (74) 
12 (75) 
3 (100) 
 
19 (29) 
10 (26) 
4 (25) 
0 (0) 
 
15 (33) 
11 (38) 
7 (58) 
0 (0) 
 
31 (67) 
18 (62) 
5 (42) 
3 (100) 
Breslow 
thickness 
<0.75 mm 
>=0.75 mm 
not stated 
 
 
19 (46) 
7 (50) 
14 (21) 
 
 
22 (54) 
7 (50) 
54 (79) 
 
 
30 (73) 
11 (79) 
49 (72) 
 
 
11 (27) 
3 (21) 
19 (28) 
 
 
12 (40) 
6 (55) 
15 (31) 
 
 
18 (60) 
5 (45) 
34 (69) 
#Wild-type here denotes an MC1R allele that does not carry any of the eight variants we 
measured (listed in Table 4).
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Table 2. Association between phenotypic factors and BRAF V600 mutations in 
cutaneous melanoma 
 
Characteristic BRAF V600 mutation
n= 40 
BRAF V600 wild-type 
n= 83 
OR (95%CI)* 
Total nevus count 
 0-15 
 16-60 
 >60 
 missing 
 
2 (6) 
19 (41) 
17 (46) 
2 (40) 
 
33 (94) 
27 (59) 
20 (54) 
3  
 
1.0 (ref) 
10.9 (2.3-51.6) 
11.9 (2.3-61.2) 
Contiguous neval remnants 
 No 
 Yes 
 
17 (22) 
23 (49) 
 
59 (78) 
24 (51) 
 
1.0 (ref) 
2.7 (1.2-6.2) 
Propensity to tan 
   Light or no tan 
   Mod/Deep tan 
   missing 
 
13 (21) 
27 (45) 
 
 
48 (79) 
33 (55) 
2  
 
1.0 (ref) 
4.3 (1.8-10.4) 
Freckles Face 
 None 
 Few 
 Many 
 missing 
 
14 (36) 
14 (31) 
12 (32) 
 
25 (64) 
31 (69) 
26 (68) 
1 (100) 
 
1.0 (ref) 
0.7 (0.3-1.8) 
0.6 (0.2-1.6) 
Eye Color 
   Blue and green 
   Black or Brown 
   missing 
 
23 (33) 
15 (31) 
2 (40) 
 
47 (67) 
33 (69) 
3 (60) 
 
1.0 (ref) 
0.8 (0.3-1.9) 
Hair Color 
   Black/Brown 
   Blondes 
   Red 
 missing 
 
30 (33) 
9 (39) 
1 (11) 
 
60 (67) 
14 (61) 
8 (89) 
1 (100) 
 
1.0 (ref) 
1.1 (0.4-2.9) 
0.2 (0.0-1.9) 
Tumor site 
 Trunk and limbs 
 Head & neck 
 
13 (30) 
27 (35) 
 
36 (70) 
47 (65) 
 
1.0 (ref) 
1.4 (0.6-3.1) 
Ambient Sun Exposure 
   Low 
   Medium 
   High 
 missing 
 
17 (44) 
15 (37) 
8 (19) 
 
22 (56) 
25 (63) 
35 (81) 
1 (100) 
 
1.0 (ref) 
1.0 (0.4-2.7) 
0.5 (0.2-1.4) 
Total Number of Solar Keratosis 
   None 
   1-20 
   >20 
   missing 
 
22 (51) 
12 (34) 
4 (10) 
2 (40) 
 
21 (49) 
23 (66) 
36 (90) 
3 (60) 
 
1.0 (ref) 
0.6 (0.2-1.7) 
0.1 (0.0-0.5) 
Propensity to sun burn 
   Rare/Never/Some 
   Mostly Burn 
   Always Burn 
   missing 
 
13 (38) 
18 (42) 
9 (20) 
 
 
21 (62) 
25 (58) 
35 (80) 
2 (100) 
 
1.0 (ref) 
0.9 (0.3-2.5) 
0.3 (0.1-0.9) 
Number of sun burns since school 
   Never 
   1-5 
   6-20 
   >20 
 missing 
 
5 (56) 
16 (30) 
17 (36) 
2 (17) 
 
 
4 (44) 
37 (70) 
30 (64) 
10 (83) 
2 (2.5) 
 
1.0 (ref) 
0.3 (0.1-1.4) 
0.4 (0.1-2.0) 
0.2 (0.0-1.4) 
*Odds ratio and 95% confidence interval, adjusted for age stratum (<50, 50+) and sex
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Table 3. Association between risk factors and BRAF V600 mutations in cutaneous 
melanoma: stepwise logistic regression model 
 
Characteristic OR (95%CI)* 
Total nevus count 
 0-15 
 16-60 
 >60 
 
1.0 (ref) 
11.8 (2.4-57.7) 
9.7 (1.8-52.1) 
Contiguous neval remnants  
 No 
 Yes 
 
1.0 (ref) 
3.1 (1.2-8.1) 
*Odds ratio and 95% confidence interval, adjusted for age stratum (<50, 50+), sex and all 
other terms in table
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Table 4. Estimated allele frequency of MC1R variants  
Variant 
Allele 
Frequency (%) 
in Tumors 
 
Frequency (%) in 
South East 
Queensland population
 (Duffy et al., 2004) 
Frequency (%) in 
melanoma patients by 
direct sequencing 
(Kanetsky et al., 2006) 
R142H 1.5 0.4 1.0 
V60L 12.3 12.2 13.3 
D84E 1.2 1.2 1.8 
R151C 15.0 11.0 13.2 
R160W 6.9 7.0 9.8 
D294H 2.7 2.7 2.8 
V92M 10.8 9.7 10.0 
R163Q 5 4.7 4.2 
All other 
variants 
Not done 0.9 4.0 
    
r 28.1 26.6 27.5 
R 27.3 22.3 28.6 
r =V60L, V92M, R163Q 
R= R142H, D84E, R151C, R160W, D294H 
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Table 5. The lack of association between MC1R and BRAF  
                                BRAF V600 
MC1R   WT   Mutant  OR (95% CI)* 
All lesions  
WT/WT   21 (64)   12 (36)   ref 
Any variant   62 (69)   28 (31)   0.72 (0.28-1.82) 
Total   83   40                
            
Intermittent sun exposed lesions (Trunk and upper limbs and lower limbs) 
WT/WT   7 (64)   4 (36)   ref 
Any variant   28 (76)   9 (24)   0.4 (0.07-2.14) 
Total   35   13               
             
Chronic sun exposed lesions (Head, neck) 
WT/WT   13 (62)   8 (38)   ref 
Any variant   33 (63)   19 (37)   0.98 (0.31-2.93) 
Total   46   27               
            
Lower category of sun exposure (0-5 actinic keratosis) 
WT/WT   4 (40)   6 (60)   ref 
Any variant   17 (52)   16 (48)   0.68 (0.21-2.22) 
Total   21   22               
            
High category of sun exposure (6+ actinic keratosis) 
WT/WT   16 (73)   6 (27)   ref 
Any variant   43 (81)   10 (19)   0.69 (0.14-3.31) 
Total   59   16               
            
Low sun exposure (low exposure history) 
WT/WT   9 (47)   10 (53)   ref 
Any variant   38 (63)   22 (37)   0.76 (0.19-2.97) 
Total   47   32               
            
High sun exposure (High exposure history) 
WT/WT   12 (86)   2 (14)   ref 
Any variant   23 (79)   6 (21)   0.77 (0.21-2.84) 
Total   35   8               
*Odds ratio and 95% confidence interval, adjusted for age and sex. 
There were 2 lesions missing site location information, 5 lesions missing actinic keratosis information and 
1 lesion missing sun exposure history. 
#WT/WT here denotes an MC1R allele that does not carry any of the eight variants we measured (listed in 
Table 4). 
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Figure legend 
 
Figure 1.  The divergent molecular pathway model of melanoma development 
incorporates molecular, environmental and phenotypic data. 
 
 
 
